Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.67 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.67 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.67 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478459 | 0.87 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL5476744 | 0.86 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL5474098 | 0.86 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL5482228 | 0.84 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL5470525 | 0.83 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL18324914 | 0.81 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3877313 | 0.81 | PTK2 (0.64) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3877071 | 0.80 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3533400 | 0.80 | MAPK14 (0.95) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL13741201 | 0.80 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | MAPK1, NOS1, NOS2 | MAPK14 12/4885MAPK13 5/4885MAPK12 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.